{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T05:04:55Z","timestamp":1794027895619,"version":"4.8.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:00:00Z","timestamp":1725580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:00:00Z","timestamp":1725580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"DOI":"10.1186\/s12872-024-04142-0","type":"journal-article","created":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T05:02:17Z","timestamp":1725598937000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Assessing the effect of high-dose rosuvastatin in elderly patients over 75 with acute coronary syndrome"],"prefix":"10.1186","volume":"24","author":[{"given":"Maryam","family":"Taherkhani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeinab","family":"Khanifar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adineh","family":"Taherkhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamed","family":"Hajishah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arian","family":"Tavasol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,6]]},"reference":[{"issue":"4","key":"4142_CR1","doi-asserted-by":"publisher","first-page":"362","DOI":"10.4997\/JRCPE.2009.425","volume":"39","author":"KS Lyons","year":"2009","unstructured":"Lyons KS, Harbinson M. Statins: in the beginning. J Royal Coll Physicians Edinb. 2009;39(4):362\u20134.","journal-title":"J Royal Coll Physicians Edinb"},{"issue":"9493","key":"4142_CR2","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","volume":"366","author":"C Baigent","year":"2005","unstructured":"Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet (London England). 2005;366(9493):1267\u201378.","journal-title":"Lancet (London England)"},{"issue":"1","key":"4142_CR3","first-page":"Cd004816","volume":"2013","author":"F Taylor","year":"2013","unstructured":"Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;2013(1):Cd004816.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"4142_CR4","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1253\/circj.CJ-10-0110","volume":"74","author":"Q Zhou","year":"2010","unstructured":"Zhou Q, Liao JK. Pleiotropic effects of statins. - basic research and clinical perspectives. Circulation Journal: Official J Japanese Circulation Soc. 2010;74(5):818\u201326.","journal-title":"Circulation Journal: Official J Japanese Circulation Soc"},{"key":"4142_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.phrs.2014.03.002","volume":"88","author":"CR Sirtori","year":"2014","unstructured":"Sirtori CR. The pharmacology of statins. Pharmacol Res. 2014;88:3\u201311.","journal-title":"Pharmacol Res"},{"key":"4142_CR6","doi-asserted-by":"crossref","unstructured":"Byrne P, Demasi M, Jones M, Smith SM, O\u2019Brien KK, DuBroff R. Evaluating the association between low-density lipoprotein cholesterol reduction and relative and absolute effects of statin treatment: a systematic review and meta-analysis. JAMA Intern Med. 2022.","DOI":"10.1001\/jamainternmed.2022.0134"},{"key":"4142_CR7","unstructured":"Shuhaili MFRMA, Samsudin IN, Stanslas J, Hasan S, Thambiah SC. Effects of different types of statins on lipid profile: a perspective on asians. Int J Endocrinol Metabolism. 2017;15(2)."},{"issue":"2","key":"4142_CR8","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/j.1365-2710.2009.01085.x","volume":"35","author":"TC Weng","year":"2010","unstructured":"Weng TC, Yang YH, Lin SJ, Tai SH. A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharm Ther. 2010;35(2):139\u201351.","journal-title":"J Clin Pharm Ther"},{"issue":"3","key":"4142_CR9","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/j.1742-1241.2008.01979.x","volume":"63","author":"M Rizzo","year":"2009","unstructured":"Rizzo M, Berneis K, Spinas G, Rini G, Kapur N. Quantitative and qualitative effects of rosuvastatin on LDL-cholesterol: what is the clinical significance? Int J Clin Pract. 2009;63(3):478\u201385.","journal-title":"Int J Clin Pract"},{"issue":"6","key":"4142_CR10","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1067\/mhj.2002.128049","volume":"144","author":"AG Olsson","year":"2002","unstructured":"Olsson AG, Istad H, Luurila O, Ose L, Stender S, Tuomilehto J, et al. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am Heart J. 2002;144(6):1044\u201351.","journal-title":"Am Heart J"},{"issue":"3","key":"4142_CR11","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1185\/03007995.2012.657302","volume":"28","author":"C Meek","year":"2012","unstructured":"Meek C, Wierzbicki AS, Jewkes C, Twomey PJ, Crook MA, Jones A, et al. Daily and intermittent rosuvastatin 5\u00a0mg therapy in statin intolerant patients: an observational study. Curr Med Res Opin. 2012;28(3):371\u20138.","journal-title":"Curr Med Res Opin"},{"issue":"17","key":"4142_CR12","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","volume":"36","author":"ES Stroes","year":"2015","unstructured":"Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, et al. Statin-associated muscle symptoms: impact on statin therapy\u2014European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015;36(17):1012\u201322.","journal-title":"Eur Heart J"},{"issue":"3","key":"4142_CR13","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1517\/14740338.2011.540568","volume":"10","author":"TT Abd","year":"2011","unstructured":"Abd TT, Jacobson TA. Statin-induced myopathy: a review and update. Exp Opin Drug Saf. 2011;10(3):373\u201387.","journal-title":"Exp Opin Drug Saf"},{"issue":"5","key":"4142_CR14","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s11883-007-0050-3","volume":"9","author":"KA Sewright","year":"2007","unstructured":"Sewright KA, Clarkson PM, Thompson PD. Statin myopathy: incidence, risk factors, and pathophysiology. Curr Atheroscler Rep. 2007;9(5):389\u201396.","journal-title":"Curr Atheroscler Rep"},{"issue":"1","key":"4142_CR15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2165\/13168600-000000000-00000","volume":"10","author":"MS Kostapanos","year":"2010","unstructured":"Kostapanos MS, Milionis HJ, Elisaf MS. Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia. Am J Cardiovasc Drugs: Drugs Devices Other Interventions. 2010;10(1):11\u201328.","journal-title":"Am J Cardiovasc Drugs: Drugs Devices Other Interventions"},{"key":"4142_CR16","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.ijcard.2015.03.373","volume":"187","author":"SW Lai","year":"2015","unstructured":"Lai SW, Lin CL, Liao KF. Rosuvastatin and risk of acute pancreatitis in a population-based case-control study. Int J Cardiol. 2015;187:417\u201320.","journal-title":"Int J Cardiol"},{"issue":"1","key":"4142_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.atherosclerosissup.2014.04.001","volume":"15","author":"NA Sattar","year":"2014","unstructured":"Sattar NA, Ginsberg H, Ray K, Chapman MJ, Arca M, Averna M, et al. The use of statins in people at risk of developing diabetes mellitus: evidence and guidance for clinical practice. Atherosclerosis Supplements. 2014;15(1):1\u201315.","journal-title":"Atherosclerosis Supplements"},{"issue":"21","key":"4142_CR18","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","volume":"359","author":"PM Ridker","year":"2008","unstructured":"Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr., Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195\u2013207.","journal-title":"N Engl J Med"},{"key":"4142_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12944-019-1182-5","volume":"19","author":"S Yu","year":"2020","unstructured":"Yu S, Jin J, Chen Z, Luo X. High-intensity statin therapy yields better outcomes in acute coronary syndrome patients: a meta-analysis involving 26,497 patients. Lipids Health Dis. 2020;19:1\u201314.","journal-title":"Lipids Health Dis"},{"key":"4142_CR20","doi-asserted-by":"crossref","unstructured":"Lis A, Lis P, \u0141owicka W, Grabarczyk M, Wita M, \u017barczy\u0144ski P et al. Lipid-lowering treatment and the lipid goals attainment in patients with a very high Cardiovascular risk. J Cardiovasc Dev Dis. 2023;10(8).","DOI":"10.3390\/jcdd10080329"},{"issue":"7","key":"4142_CR21","first-page":"e41402","volume":"15","author":"PM Wambua","year":"2023","unstructured":"Wambua PM, Khan Z, Kariuki CM, Ogola EN. A retrospective study on the Adoption of Lipid Management Guidelines in post-myocardial infarction patients in a Tertiary Care Centre. Cureus. 2023;15(7):e41402.","journal-title":"Cureus"},{"key":"4142_CR22","doi-asserted-by":"crossref","unstructured":"Luo R, Sun X, Shen F, Hong B, Wang Z. Effects of high-dose rosuvastatin on ventricular remodelling and cardiac function in ST-segment elevation myocardial infarction. Drug Design, Development and Therapy. 2020:3891-8.","DOI":"10.2147\/DDDT.S254948"},{"issue":"6","key":"4142_CR23","doi-asserted-by":"publisher","first-page":"743","DOI":"10.3892\/br.2015.500","volume":"3","author":"S Mythili","year":"2015","unstructured":"Mythili S, Malathi N. Diagnostic markers of acute myocardial infarction. Biomedical Rep. 2015;3(6):743\u20138.","journal-title":"Biomedical Rep"},{"issue":"1","key":"4142_CR24","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/MCA.0b013e32834e4ef1","volume":"23","author":"DM Lofthus","year":"2012","unstructured":"Lofthus DM, Stevens SR, Armstrong PW, Granger CB, Mahaffey KW. Pattern of liver enzyme elevations in acute ST-elevation myocardial infarction. Coron Artery Dis. 2012;23(1):22\u201330.","journal-title":"Coron Artery Dis"},{"key":"4142_CR25","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2165\/13168600-000000000-00000","volume":"10","author":"MS Kostapanos","year":"2010","unstructured":"Kostapanos MS, Milionis HJ, Elisaf MS. Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia. Am J Cardiovasc Drugs. 2010;10:11\u201328.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"22","key":"4142_CR26","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1056\/NEJMoa0706201","volume":"357","author":"J Kjekshus","year":"2007","unstructured":"Kjekshus J, Apetrei E, Barrios V, B\u00f6hm M, Cleland JG, Cornel JH, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357(22):2248\u201361.","journal-title":"N Engl J Med"},{"key":"4142_CR27","doi-asserted-by":"crossref","unstructured":"Zhao W, Zhao S-P. Different effects of statins on induction of diabetes mellitus: an experimental study. Drug design, development and therapy. 2015:6211-23.","DOI":"10.2147\/DDDT.S87979"},{"issue":"13","key":"4142_CR28","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1001\/jama.289.13.1681","volume":"289","author":"PD Thompson","year":"2003","unstructured":"Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA. 2003;289(13):1681\u201390.","journal-title":"JAMA"},{"issue":"5","key":"4142_CR29","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.amjmed.2006.02.007","volume":"119","author":"KA Antons","year":"2006","unstructured":"Antons KA, Williams CD, Baker SK, Phillips PS. Clinical perspectives of statin-induced rhabdomyolysis. Am J Med. 2006;119(5):400\u20139.","journal-title":"Am J Med"},{"key":"4142_CR30","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.toxlet.2016.10.017","volume":"265","author":"SO El-Ganainy","year":"2017","unstructured":"El-Ganainy SO, El-Mallah A, Abdallah D, Khattab MM, Mohy El-Din MM, El-Khatib AS. Rosuvastatin safety: an experimental study of myotoxic effects and mitochondrial alterations in rats. Toxicol Lett. 2017;265:23\u20139.","journal-title":"Toxicol Lett"},{"issue":"6","key":"4142_CR31","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1592\/phco.30.6.541","volume":"30","author":"S Cham","year":"2010","unstructured":"Cham S, Evans MA, Denenberg JO, Golomb BA. Statin-associated muscle\u2010related adverse effects: a case series of 354 patients. Pharmacotherapy: J Hum Pharmacol Drug Therapy. 2010;30(6):541\u201353.","journal-title":"Pharmacotherapy: J Hum Pharmacol Drug Therapy"},{"issue":"13","key":"4142_CR32","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1001\/jama.285.13.1711","volume":"285","author":"GG Schwartz","year":"2001","unstructured":"Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285(13):1711\u20138.","journal-title":"JAMA"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-024-04142-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-024-04142-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-024-04142-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T05:03:14Z","timestamp":1725598994000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-024-04142-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,6]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4142"],"URL":"https:\/\/doi.org\/10.1186\/s12872-024-04142-0","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,6]]},"assertion":[{"value":"31 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"474"}}